- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Proair digihaler (albuterol sulfate) / Teva
Journal: Dry powder inhalers: a concise summary of the electronic monitoring devices. (Pubmed Central) - Apr 30, 2021 IND/GLY/MF high-dose o.d. improved lung function, asthma control and health status versus SAL/FLU high dose + TIO, while IND/GLY/MF medium-dose had comparable efficacy but at a corresponding lower steroid dose. No abstract available
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Clinical, Journal: Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. (Pubmed Central) - Jan 30, 2021 P2 In conclusion, both doses of IND/GLY/MF provided superior lung function benefits compared with twice-daily, standard-of-care SFC at the highest approved dose. TRIAL REGISTRATION: ClinicalTrials.gov, (Identifier: NCT03063086), EudraCT start date: May 11, 2017; First patient first visit / study initiation date: May 31, 2017.
- |||||||||| Xolair (omalizumab) / Roche, Novartis, Onbrez (indacaterol) / Novartis
Journal: Drugs for asthma. (Pubmed Central) - Jan 26, 2021 TRIAL REGISTRATION: ClinicalTrials.gov, (Identifier: NCT03063086), EudraCT start date: May 11, 2017; First patient first visit / study initiation date: May 31, 2017. No abstract available
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
[VIRTUAL] TRIPLE THERAPY (ICS/LABA/LAMA) IN PATIENTS WITH UNCONTROLLED ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS () - Nov 21, 2020 - Abstract #ACAAI2020ACAAI_561; FEV1 in the triple therapy group was also increased compared to the ICS/LABA therapy (FEV1 80mL, 95% CI 50 to 100, I2=48%. p-value <0.00001, high certainty).Conclusions These findings support LAMA add-on therapy in patients with uncontrolled, persistent asthma despite treatment with ICS/LABA.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Trial initiation date: XPERTT: Investigating the Effects of QVM149 on MRI Ventilation Defects (clinicaltrials.gov) - Oct 5, 2020 P3, N=48, Not yet recruiting, CLINICAL IMPLICATIONS: The proportion of patients with exacerbations was found to increase with increasing SABA use. Initiation date: Sep 2020 --> Dec 2020
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Examination of clinical effects of ICS / LABA / LAMA preparations () - Sep 11, 2020 - Abstract #WAC2020WAC_1172; At a willingness-to-pay threshold of $50,000/QALY, treatment with IND/GLY/MF is cost-effective in patients with uncontrolled moderate-to-severe asthma compared with SAL/FLU+Tio or SAL/FLU from a Canadian health care payer perspective. The password to see abstracts was announced to registrants by email.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Journal: Trends over time in COPD treatment choices by respiratory physicians: An analysis from the COLIBRI-COPD French cohort. (Pubmed Central) - Aug 27, 2020 Triple ICS/LABA/LAMA FDC and dual LABA/LAMA or ICS/LABA FDCs are characterized by specific efficacy/safety profiles in agreement with the level of blood eosinophil count at baseline. Changes over time in therapeutic profiles suggest that new evidence from scientific publications and recommendations may have had a rapid impact on clinical practice.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
[VIRTUAL] Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients (Channel 2) - Aug 21, 2020 - Abstract #ERS2020ERS_5541; On top salbutamol did not significantly (P>0.05) improve R5-19Hz neither at peak (-12.9±2.6% vs. pre-salbutamol) nor at trough (-31.6±6.0% vs. pre-salbutamol). Conclusion This study demonstrates that BDP/FF/GB 87/5/9 ug is capable of inducing ceiling bronchodilation at the level of small airways of severe asthmatic patients.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Clinical, Clinical guideline, Journal: Pharmacologic Management of COPD: An Official American Thoracic Society Clinical Practice Guideline. (Pubmed Central) - Aug 15, 2020 The task force made recommendations on the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are under-represented in clinical trials is needed, including studies in COPD patients 80 years of age and older, those with multiple chronic health conditions, and those with a co-diagnosis of COPD and asthma.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Diagnosis and drug therapy based on the pathology of ACO (p.608) - Aug 2, 2020 - Abstract #WAC2020WAC_220; ACO may be useful in combination with LAMA in patients who are poorly controlled with medium-dose ICS / LABA In that sense, the triple preparation of ICS / LABA / LAMA can be said to be a useful therapeutic agent for ACO. In this lecture, In addition to diagnosis and treatment based on the condition, we report on the current problems and future prospects.
- |||||||||| doxycycline / Generic mfg., Pierre Fabre
Journal: Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study. (Pubmed Central) - Aug 2, 2020 These data suggest that the improvement in lung function and quality of life in COPD patients may probably be attributed to the antioxidant, anti-inflammatory and anti-MMP activity of doxycycline. The potential therapeutic role of long-term doxycycline, in addition to its traditional antibiotic effect, definitely warrants further attention.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Clinical, Journal: A potential role of triple therapy for asthma patients. (Pubmed Central) - Jul 29, 2020 We believe that it is appropriate to treat with triple therapy asthmatic patients who have smoked and remain symptomatic or suffer from frequent exacerbations despite initial inhaler therapy with ICS/LABA. However, we must establish when to step up or mainly step down triple therapy especially in patients who are well controlled, and what will be the cost of these combinations in the management of asthma.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Journal, HEOR: Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. (Pubmed Central) - Jul 22, 2020 P=N/A The results of the random effects log-linear panel data regression model may help clinicians estimate INHS costs when managing COPD patients. Clinicaltrials.gov ID# NCT02689492.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] IND/GLY/MF: synergism in medium and small human hyperresponsive airways (Pre-congress content) - Jul 15, 2020 - Abstract #ERS2020ERS_2158; Conclusion IND/GLY/MF synergistically relaxed hyperresponsive human isolated medium and small airways in ex vivo models of bronchial asthma. Funding This study was supported by Novartis Pharma AG, Basel, Switzerland.
|